DM Corporation and ORF Genetics to Collaborate on Protein Drugs
An MOU Signed During Official Visit of Mrs. Preneet Kau, Indian Minister of State for External Affairs, to Iceland
The MOU states that the companies will form a joint venture to develop and market human recombinant therapeutic proteins and biosimilars. DM Corporation will bring to the collaboration expertise in management of pre-clinical research, clinical development and marketing. ORF Genetics will supply its expertise in plant genetics and protein biochemistry, including its proprietary Orfeus(TM) protein production system in genetically modified barley. The Orfeus (TM) platform was developed to produce high-quality recombinant proteins on a large scale, bypassing production in E. coli, yeast or mammalian cells.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.